Scarica l'app Stockscreener
81.61
3.06%
2.42
Pre-mercato:
81.61
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$79.19
Aprire:
$79.44
Volume 24 ore:
1.81M
Relative Volume:
0.99
Capitalizzazione di mercato:
$15.94B
Reddito:
$4.41B
Utile/perdita netta:
$21.27M
Rapporto P/E:
255.03
EPS:
0.32
Flusso di cassa netto:
$288.81M
1 W Prestazione:
+5.00%
1M Prestazione:
+18.98%
6M Prestazione:
+18.19%
1 anno Prestazione:
+33.52%
Intervallo 1D:
$79.33
$81.82
Intervallo di 1 settimana:
$76.45
$81.82
Portata 52W:
$53.56
$83.95
Incyte Corp Stock (INCY) Company Profile
Nome
Incyte Corp
Settore
Industria
Telefono
(302) 498-6700
Indirizzo
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Confronta INCY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
81.61 | 15.46B | 4.41B | 21.27M | 288.81M | 0.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-08-01 | Iniziato | Barclays | Overweight |
| 2025-06-16 | Aggiornamento | Stifel | Hold → Buy |
| 2025-03-18 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-03-18 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | Iniziato | UBS | Neutral |
| 2024-10-29 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-10-01 | Iniziato | Wolfe Research | Outperform |
| 2024-09-18 | Downgrade | Truist | Buy → Hold |
| 2024-07-02 | Downgrade | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | Iniziato | Deutsche Bank | Hold |
| 2024-04-23 | Iniziato | Cantor Fitzgerald | Neutral |
| 2024-02-23 | Iniziato | Jefferies | Buy |
| 2024-02-14 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-11-21 | Downgrade | Goldman | Buy → Neutral |
| 2023-07-25 | Iniziato | Citigroup | Buy |
| 2023-05-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-04-10 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | Aggiornamento | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | Iniziato | Piper Sandler | Overweight |
| 2022-08-03 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-08-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-07-28 | Iniziato | Wells Fargo | Equal Weight |
| 2022-02-09 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-07-20 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-02-10 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | Iniziato | Truist | Buy |
| 2021-01-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-06-16 | Iniziato | The Benchmark Company | Hold |
| 2020-05-06 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-04-29 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | Ripresa | William Blair | Outperform |
| 2020-03-13 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | Ripresa | BofA/Merrill | Neutral |
| 2020-01-03 | Reiterato | BMO Capital Markets | Market Perform |
| 2020-01-03 | Downgrade | Mizuho | Buy → Neutral |
| 2020-01-02 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-10-03 | Iniziato | Mizuho | Buy |
| 2019-09-12 | Iniziato | BMO Capital Markets | Market Perform |
| 2019-09-05 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | Ripresa | Morgan Stanley | Equal-Weight |
| 2019-09-05 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2019-05-21 | Iniziato | Credit Suisse | Neutral |
| 2019-05-03 | Downgrade | Barclays | Overweight → Equal Weight |
| 2019-04-11 | Iniziato | Stifel | Hold |
| 2019-04-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | Aggiornamento | William Blair | Mkt Perform → Outperform |
Mostra tutto
Incyte Corp Borsa (INCY) Ultime notizie
Wells Fargo Upgrades Incyte Corporation (INCY) to Overweight From Equal Weight - Insider Monkey
Semerjian to lead Geron - BioCentury
Incyte EVP Denton sells $45k in shares after option exercise - Investing.com Nigeria
Incyte EVP Denton sells $45k in shares after option exercise By Investing.com - Investing.com South Africa
Incyte (INCY) Analyst Rating: Wells Fargo Upgrades to Overweight - GuruFocus
Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer - The Manila Times
Mallinckrodt appoints Incyte’s Christiana Stamoulis as new CFO - Investing.com
Wells Fargo Upgrades Incyte to Overweight From Equalweight, Adjusts Price Target to $89 From $67 - MarketScreener
Incyte Announces Departure of Chief Financial Officer Christiana Stamoulis - BioSpace
Incyte CFO Christiana Stamoulis to step down in September - Investing.com
Incyte CFO Christiana Stamoulis to step down in September By Investing.com - Investing.com UK
Argus Research Adjusts Incyte Price Target to $90 From $75 - MarketScreener
Knight Therapeutics and Incyte Amend Supply and Distribution Agreement to Add Retifanlimab and Axatilimab in Latin America - The Manila Times
Mizuho Securities Adjusts Incyte Price Target to $74 From $70 - MarketScreener
Incyte rises on results beat, lifted Jakafi guidance - MSN
Incyte's (INCY) "Neutral" Rating Reiterated at UBS Group - MarketBeat
Is it the right time to buy Incyte Corporation stockUnlock powerful investment tools for free - Jammu Links News
What makes Incyte Corporation stock price move sharplyBuild wealth faster with expert stock picks - Jammu Links News
Citigroup Issues Positive Forecast for Incyte (NASDAQ:INCY) Stock Price - MarketBeat
Barclays Initiates Incyte With Overweight Rating, $90 Price Target, Retail Finds Reason To Cheer - Stocktwits
Incyte's new CEO outlines growth plan as Jakafi patent cliff nears - MSN
Barclays Initiates Coverage on INCY with Overweight Rating and $90 Price Target | INCY Stock News - GuruFocus
This Incyte Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Friday - Benzinga
Barclays initiates coverage on Incyte stock with Overweight rating By Investing.com - Investing.com Canada
Barclays initiates coverage on Incyte stock with Overweight rating - Investing.com
Incyte's Stock Price Target Raised by RBC Capital to $72.00 - AInvest
Incyte (INCY) Receives Overweight Rating and $90 Price Target fr - GuruFocus
Why is Incyte Corporation stock attracting strong analyst attentionBest Dividend Insights For Consistent Profits - Jammu Links News
Incyte’s Earnings Call: Strong Growth Amid Challenges - The Globe and Mail
INCY's Q2 Earnings & Revenues Beat Estimates on Higher Product Sales - MSN
Incyte stock price target raised to $72 from $68 at RBC Capital - Investing.com Nigeria
Incyte stock price target raised to $72 from $68 at RBC Capital By Investing.com - Investing.com South Africa
Incyte stock price target raised to $60 from $52 at BMO Capital - Investing.com Canada
Incyte stock price target raised to $60 from $52 at BMO Capital By Investing.com - Investing.com South Africa
Incyte Corporation (NASDAQ:INCY) Q2 2025 Earnings Call Transcript - Insider Monkey
Sun Pharma settles litigation with Incyte Corp over hair loss drug Leqselvi - MSN
Incyte: Q2 Earnings Snapshot - Huron Daily Tribune
Incyte Corp (INCY) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
Incyte Corp (INCY) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Incyte Raises Its Outlook After Beating Expectations On Jakafi Sales - Finimize
Incyte stock price target raised to $79 by Truist on strong Jakafi sales - Investing.com Canada
Incyte stock price target raised to $89 from $86 at TD Cowen on strong Q2 - Investing.com Canada
Incyte stock price target raised to $89 from $86 at TD Cowen on strong Q2 By Investing.com - Investing.com South Africa
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Incyte earnings beat by $0.17, revenue fell short of estimates - Investing.com
Incyte’s Blood Cancer Drug Sales Forecast Gets A Lift - Finimize
Incyte Corp Azioni (INCY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.91%
8.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):